AOD 9604 is a modified peptide initially developed as an offshoot in obesity research. It modifies the peptide fragment 176-191 of the growth hormone HGH by adding a tyrosine residue to the N-terminus. The proposed mode of action of AOD 9604 has been suggested by researchers to be restricted to promoting lipolysis, thus linking the synthetic compound to obesity research.[1] The peptide does not appear to affect levels of insulin or IGF1 in studies thus far; therefore, it may not trigger diabetes development or induce glucose intolerance in test models, though further studies are necessary to explore this aspect